NCT02337517View on ClinicalTrials.gov

Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

September 8, 2015

Primary Completion Date

June 28, 2018

Study Completion Date

June 28, 2018

Conditions
Chronic Graft Versus Host Disease
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Vismodegib

Given PO

Trial Locations (2)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

National Cancer Institute (NCI)

NIH